Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP protection, and patient tolerability, writes Enveric Biosciences CEO Joseph ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

On this weeks Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity losses and medical treatment ...

We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may ...

EYs Arda Ural provides an assessment of the current life sciences business environment, and reasons for optimism about 2025 despite the uncertainty that comes with a new administration in the U.S.

Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly ...

When engaging in the bidding process, pharmaceutical manufacturers and medical device companies must match the sophistication of the PBM/GPO entities through careful strategic planning that considers ...